322 related articles for article (PubMed ID: 21816640)
1. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Lin J; Zahurak M; Beer TM; Ryan CJ; Wilding G; Mathew P; Morris M; Callahan JA; Gordon G; Reich SD; Carducci MA; Antonarakis ES
Urol Oncol; 2013 Jul; 31(5):581-8. PubMed ID: 21816640
[TBL] [Abstract][Full Text] [Related]
2. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.
Antonarakis ES; Zahurak ML; Lin J; Keizman D; Carducci MA; Eisenberger MA
Cancer; 2012 Mar; 118(6):1533-42. PubMed ID: 21960118
[TBL] [Abstract][Full Text] [Related]
3. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
Lee M; Hong H; Kim W; Zhang L; Friedlander TW; Fong L; Lin AM; Small EJ; Wei XX; Rodvelt TJ; Miralda B; Stocksdale B; Ryan CJ; Aggarwal R
Clin Genitourin Cancer; 2019 Feb; 17(1):e92-e96. PubMed ID: 30327180
[TBL] [Abstract][Full Text] [Related]
4. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Liu G; Chen YH; Kolesar J; Huang W; Dipaola R; Pins M; Carducci M; Stein M; Bubley GJ; Wilding G
Urol Oncol; 2013 Feb; 31(2):211-8. PubMed ID: 21784672
[TBL] [Abstract][Full Text] [Related]
5. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.
Paller CJ; Ye X; Wozniak PJ; Gillespie BK; Sieber PR; Greengold RH; Stockton BR; Hertzman BL; Efros MD; Roper RP; Liker HR; Carducci MA
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):50-5. PubMed ID: 22689129
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
8. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
[TBL] [Abstract][Full Text] [Related]
10. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
Keizman D; Huang P; Antonarakis ES; Sinibaldi V; Carducci MA; Denmeade S; Kim JJ; Walczak J; Eisenberger MA
Prostate; 2011 Nov; 71(15):1608-15. PubMed ID: 21432863
[TBL] [Abstract][Full Text] [Related]
11. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
Pantuck AJ; Pettaway CA; Dreicer R; Corman J; Katz A; Ho A; Aronson W; Clark W; Simmons G; Heber D
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):242-8. PubMed ID: 26169045
[TBL] [Abstract][Full Text] [Related]
13. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
[TBL] [Abstract][Full Text] [Related]
14. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Markowski MC; Chen Y; Feng Z; Cullen J; Trock BJ; Suzman D; Antonarakis ES; Paller CJ; Rosner I; Han M; Walsh PC; Partin AW; Eisenberger M
Clin Genitourin Cancer; 2019 Dec; 17(6):470-475.e1. PubMed ID: 31530439
[TBL] [Abstract][Full Text] [Related]
15. A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
van Die MD; Williams SG; Emery J; Bone KM; Taylor JM; Lusk E; Pirotta MV
Prostate; 2017 May; 77(7):765-775. PubMed ID: 28181675
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
17. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
Schröder FH; Bangma CH; Wolff JM; Alcaraz A; Montorsi F; Mongiat-Artus P; Abrahamsson PA; McNicholas TA; Castro RS; Nandy IM
BJU Int; 2009 Mar; 103(5):590-6. PubMed ID: 19226424
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Gross ME; Agus DB; Dorff TB; Pinski JK; Quinn DI; Castellanos O; Gilmore P; Shih JC
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):61-68. PubMed ID: 32123315
[TBL] [Abstract][Full Text] [Related]
19. Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
Eisenberger MA; Laufer M; Vogelzang NJ; Sartor O; Thornton D; Neubauer BL; Sinibaldi V; Lieskovsky G; Carducci MA; Zahurak M; Raghavan D
Urology; 2004 Jan; 63(1):114-9. PubMed ID: 14751361
[TBL] [Abstract][Full Text] [Related]
20. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224).
Doñate F; Juarez JC; Burnett ME; Manuia MM; Guan X; Shaw DE; Smith EL; Timucin C; Braunstein MJ; Batuman OA; Mazar AP
Br J Cancer; 2008 Feb; 98(4):776-83. PubMed ID: 18253124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
